Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program

SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization

“…Alveolar hemorrhages have been reported, and the engraftment syndrome, 10 related to a rapid increase in the leukocyte count, may occur. 11 Splenic rupture, including rare fatal cases, has been reported; 12 bone pain is seen in approximately one-fourth of patients, 13 as is cutaneous vasculitis. 14 Previously, in our autologous stem cell program, the use of growth factor after SCT for amyloidosis was discontinued; this did not result in an increase in bacteremia or hospital days, although a minimal delay in leukocyte recovery was seen.…”

Uniform examination of stem cell donors

“…The last years, the WMDA ⁄ NMDP introduced a reporting system of SAERs in unrelated donors [35].The need for a similar registration system for related donors is widely recognized in order to come to better risk assessment of related donors. However, besides a few exceptions, even at the national levels such registries are not operative.…”

“…In the retrospective EBMT study, a follow-up questionnaire revealed that 20 out of 51 000 donors had developed a haematological malignancy between 4 months and 12 years post-donation (15 related donors and 5 not reported) [30]. The large unrelated donor registries now collect long-term outcome data of donors in a systematic prospective manner [33][34][35][36][37].…”

Allogeneic hematopoietic stem cell donation—standardized assessment of donor outcome data: A consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT)

“…[16][17][18][19] Current experience suggests that risks seem to be higher for related than for unrelated donors with the caveat of reporting bias and lack of an adequate amount of prospective follow-up data in the related donor setting. [9][10][11]18 These rare SAE/R that occur with estimates of about 1 in 3-5000 for serious and 1 in 10-20 000 for lethal events are still incompletely understood. [9][10][11][16][17][18][19] Hence, there is urgent need for better understanding of short-term SAR and to identify donors at risk.…”

“…Today, large registry studies in unrelated donors [9][10][11] form the basis for the current knowledge on the frequent side effects during BM and PBSC donation, which are usually of mild or moderate severity. Smaller studies from related donors suggest that these frequent side effects occur with the same pattern in related donors.…”